| Literature DB >> 22693599 |
Georgia A Paxton1, Katrina J Sangster, Ellen L Maxwell, Catherine R J McBride, Ross H Drewe.
Abstract
OBJECTIVE: To document the prevalence of nutritional deficiencies, infectious diseases and susceptibility to vaccine preventable diseases in Karen refugees in Australia.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22693599 PMCID: PMC3364970 DOI: 10.1371/journal.pone.0038194
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Visa Medical Examination and Pre-departure Medical Screening (PDMS) [31].
|
| |
| Height and Weight | All applicants |
| Full medical examination | All applicants |
| Urine dipstick testing | Applicants ≥5 years |
| Chest x-ray (CXR) | Aged ≥11 years and younger if any indications of TB disease or a history of contact with TB |
| Human Immunodeficiency Virus (HIV) serology | All applicants aged ≥15 years |
| Syphilis serology | All applicants aged ≥15 years |
| Hepatitis B virus (HBV) screening | International adoptees, unaccompanied minors, pregnant women |
|
| |
| Fitness to fly assessment | All applicants |
| RDT for malaria and treatment if positive | All applicants |
| Albendazole dose given | All applicants ≥6months |
| MMR vaccination given | 9 months–30 years of age |
There is variation in the timing of the visa medical examination, and uptake of PDMS and screening may be limited, especially for children. The full PDMS is used in Thailand (the port of departure for most of this cohort). A short form of PDMS is also used in some ports of departure, which is an assessment of ‘fitness to fly’.
Investigations.
| Recommended investigations | Additional investigations |
| Full blood examination (FBE) | Calcium |
| Iron studies | Phosphate |
| Liver function tests (LFT) | Vitamin B12 |
| 25-hydroxy vitamin D (25(OH)D) | Folate |
| Vitamin A (children) | Vitamin A (all ages) |
| Hepatitis B serology (surface antigen (sAg), core antibody (cAb), surface antibody (sAb)) | Thyroid function tests (TFT) |
| Hepatitis C antibodies | Measles serology |
| HIV screening | Mumps serology |
|
| Rubella serology (adolescents, adults) |
|
| Hepatitis A serology |
|
| |
| Malaria thick/thin films and immunochromatographic (ICT) testing | |
| Quantiferon-gold® | |
| Urine | |
| Fresh faecal specimen |
Done routinely at the Community Health Centre at the time.
Age and gender of Karen refugee cohort.
| Age | <6 years | 6–11 years | 12–17 years | ≥18 years | Total |
|
| 61 | 96 | 92 | 301 | 550 |
|
| 73 | 106 | 75 | 319 | 573 |
|
| - | - | 1 | 12 | 13 |
|
| 134(12%) | 202(18%) | 168(15%) | 632(55%) | 1136(100%) |
Prevalence of health issues by age group.
| Parameter | Age | ||||
| Haematology and nutrition | <6 years | 6–11 years | 12–17 years | 18 years + | Overall |
| Low haemoglobin | 23.1%(30/130) | 11.6% (23/199) | 3.0% (5/166) | 7.1% (44/618) | 9.2% (102/1113) |
| Microcytosis | 36.9%(48/130) | 23.6% (47/199) | 15% (25/167) | 15.1% (95/630) | 19.1% 215/1126 |
| Macrocytosis | 0% (0/130) | 0% (0/199) | 0% (0/167) | 0.2% (1/630) | 0.1% (1/1126) |
| Neutropaenia | 0.8% (1/130) | 0% (0/199) | 1.2% (2/167) | 1.4% (9/630) | 1.1% (12/1126) |
| Eosinophilia | 9.3% (12/129) | 9.0% (18/199) | 21.0%(35/167) | 15.4% (97/630) | 14.4%(162/1125) |
| Low ferritin | 30.2%(39/129) | 8.0% (16/201) | 10.2%(17/167) | 11.9% (75/628) | 13.1%(147/1125) |
| Low vitamin B12 | 1.9% (2/106) | 0.7% (1/135) | 0.9% (1/111) | 1.7% (8/460) | 1.5% (12/812) |
| Low folate | 1.7% (2/121) | 0.5% (1/193) | 0.6% (1/166) | 2.0% (12/614) | 1.5% (16/1094) |
| Low vitamin A | 2.6% (3/114) | 3.1% (5/160) | 0% (0/132) | 0.4% (2/515) | 1.1% (10/921) |
| Vitamin D<50 nmol/L | 30.0%(39/130) | 33.3%(67/201) | 44.3%(74/167) | 31.1%(195/627) | 33.3%(375/1125) |
| Vitamin D≤25 nmol/L | 3.1% (4/130) | 2.5% (5/201) | 7.2% (12/167) | 2.9% (18/627) | 3.5% (39/1125) |
| High ALP | 4.6% (6/130) | 4.5% (9/201) | 4.8% (8/167) | 5.7% (36/631) | 5.2% (59/1129) |
| Hypocalcaemia | 7.4% (5/68) | 7.8% (6/77) | 17.9% (14/78) | 5.0% (17/343) | 7.4% (42/566) |
|
| |||||
| Low TSH | 1.6% (2/125) | 0% (0/197) | 3.6% (6/168) | 4.9% (30/618) | 3.4% (38/1108) |
| High TSH | 0.8% (1/125) | 0% (0/197) | 0.6% (1/168) | 1.5% (9/618) | 1.0% (11/1108) |
| High ALT | 1.5% (2/130) | 4.0% (8/201) | 6.0% (10/167) | 25.7%(162/631) | 16.1%(182/1129) |
|
| |||||
| Hepatitis B sAg positive | 0% (0/78) | 4.6% (4/87) | 10.3% (8/78) | 13.4% (41/305) | 9.7% (53/548) |
| Hepatitis B cAb positive | 6.7% (5/75) | 24.1% (21/87) | 53.8% (42/78) | 74.8%(228/305) | 54.3% (296/545) |
| Hepatitis C positive | 0% (0/69) | 0% (0/74) | 0% (0/71) | 3.3% (10/305) | 1.9% (10/519) |
|
| 3.0% (4/134) | 5.4% (11/202) | 4.8% (8/168) | 9.0% (57/632) | 7.0% (80/1136) |
|
| 7.1% (9/127) | 9.3% (16/172) | 19.0%(26/137) | 28.1%(151/537) | 20.8%(202/973) |
| Malaria ICT positive | 0% (0/40) | 2.1% (2/97) | 1.4% (1/70) | 0.4% (1/238) | 0.9% (4/445) |
| Malaria film positive | 0% (0/40) | 1.0% (1/97) | 0% (0/70) | 0% (0/238) | 0.2% (1/445) |
| Faecal specimen – any cysts/ova/parasites | 39.8%(49/123) | 58.0%(112/193) | 49.7%(81/163) | 37.2%(204/548) | 43.4%(446/1027) |
| Faecal pathogens | 26.8%(33/123) | 29.5%(57/136) | 19.6%(32/131) | 9.7%(53/495) | 17.0%(175/1027) |
| Urine | - | - | 1.8% (2/109) | 0% (0/530) | 0.3% (2/649) |
| Quantiferon-gold®-positive | 5.3% (1/19) | 21.8% (12/55) | 14.9%(20/134) | 22.6%(136/602) | 20.9%(169/810) |
|
| |||||
| Measles IgG positive | 97.6% (41/42) | 87.5% (63/72) | 82.5%(94/114) | 87.3%(446/511) | 87.1%(644/739) |
| Mumps IgG positive | 78.6% (33/42) | 94.4%(68/72) | 97.4%(111/114) | 95.9%(489/510) | 95.0%(701/738) |
| Rubella IgG positive | - | - | 84.7% (50/59) | 62.3%(188/302) | 66.4%(245/369) |
| Hepatitis B sAb positive | 69.7%(53/76) | 39.1% (34/87) | 43.6%(34/78) | 48.9%(149/305) | 49.5%(270/546) |
| Hepatitis B cAb & sAb positive | 1.9% (1/53) | 38.2% (13/34) | 85.3% (29/34) | 87.2(130/149) | 64.1%(173//270) |
| Hepatitis A IgG positive | 22.7% (17/75) | 83.9% (73/87) | 89.6% (69/77) | 98.9%(274/277) | 83.9%(433/516) |
Low and high defined by reference range for age/gender. Although a proportion of the population may have results outside a reference range if it is defined according to a normal distribution; and reference ranges will not be specific to this group; in practice, most results outside the reported reference range require at least clinical assessment, and may require treatment, hence the results are reported using the reference ranges of the pathology provider.
Defined by titre ≥1: 32.
Faecal pathogens were any one of Giardia intestinalis, Entamoeba histolytica/dispar, Cyclospora cayetanensis, Hookworm, Trichuris trichiuria, Taenia spp, Strongyloides stercoralis, Enterobius vermicularis, Ascaris lumbricoides.
Defined by being Hepatitis B cAb positive where sAb was detected.